COVID Vaccines: US FDA Should Play More Activist Role In Development Of Modified Formulations

 
• By Sue Sutter

Advisory committee tells FDA that the agency, not vaccine manufacturers, should dictate the conversation around variants and reformulations; panelists also want better government research on immune correlates of protection ahead of any decision on a composition change.

Dictation
FDA's external experts want the agency, not manufacturers, to dictate the conversation on variants and new formulations for modified vaccines. • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers